Lilly, Novo Nordisk Fight Insulin Biosimilars With Tweaks to FDA Draft Guidance

As Americans with diabetes continue to die because they cannot afford their insulin, two of the three insulin manufacturers in the US are doing their best to try to alter US Food and Drug Administration (FDA) draft guidance that seeks to bring more insulin competition to market.